Fig. 1From: Enhanced effect of checkpoint inhibitors when given after or together with IMM-101: significant responses in four advanced melanoma patients with no additional major toxicitySignificant response seen in a 46 year-old male with stage IV melanoma treated with ipilimumab after IMM-101 with most of the lesions resolving and a couple remaining stable over a long period of timeBack to article page